Novartis

The company plans to start asking health authorities for approvals by year’s end Novartis’s investigational multiple sclerosis…

The programme, rolled out last year, saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process…

The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS)

The second patent cliff is around the corner, as patents for branded molecules with cumulative global sales of over $ 251 billion…

BioCamp engages students around scientific advances to address unmet medical needs and entrepreneurial opportunities and offers 50…

The company will also offer coaching to associates going on leave for a seamless reintegration into the workplace when they resume…

The Boston-based Institute for Clinical and Economic Review (ICER), which has been reviewing Mayzent for months, recommended that…

David Epstein, Division Head and Chief Executive, Novartis Pharmaceuticals to leave the company Novartis is splitting its…

Results presented at American Academy of Neurology will be discussed with health authorities for potential worldwide regulatory…

Acquires 14 prescription brands Sun Pharma has acquired 14 established prescription brands from Novartis in Japan. According to…